ライフサイエンスコーパス: human immunodeficiency virus

1 17 men [56.0%]; 187 [89.5%] positive for the human immunodeficiency virus).

2 PID), including an association with risk for human immunodeficiency virus.

3 , aged >/=40 years, white, and infected with human immunodeficiency virus.

4 sis, rubella, cytomegalovirus, syphilis, and human immunodeficiency virus.

5 and 19, herpes simplex virus (HSV) 1 and 2, human immunodeficiency virus 1, hepatitis C virus, enter

6 Human immunodeficiency virus-1 (HIV) targets the monocyt

7 Human immunodeficiency virus-1 (HIV-1) infection current

8 diseases such as tuberculosis, malaria, and human immunodeficiency virus/acquired immunodeficiency s

9 in immunocompromised individuals, typically human immunodeficiency virus/AIDS patients from developi

10 Patients with human immunodeficiency virus/AIDS-associated cryptococca

11 epatitis B surface antigen (HBsAg) positive, human immunodeficiency virus and hepatitis D virus-negat

12 facilitates transmission of less infectious human immunodeficiency virus, but highly infectious viru

13 source setting with universal free access to human immunodeficiency virus care.

14 ed patients with pulmonary tuberculosis (65% human immunodeficiency virus coinfected) were intensivel

15 istal extremities (ie, neuropathy related to human immunodeficiency virus, diabetes, or Fabry disease

16 Human immunodeficiency virus drug resistance (HIVDR) pla

17 istinct from prototypic SIV encephalitis and human immunodeficiency virus encephalitis were identifie

18 s, but there are no data to guide its use in human immunodeficiency virus/HCV coinfected kidney trans

19 We treated 6 human immunodeficiency virus/HCV coinfected kidney trans

20 ted on PrOD or LDV/SOF, excluding those with human immunodeficiency virus, hepatitis B surface antige

21 cluding rubella, congenital cytomegalovirus, human immunodeficiency virus, hepatitis B virus, and neo

22 avirus (HPV) types among women infected with human immunodeficiency virus (HIV) (WHIV) are needed to

23 SVAX B/E boost afforded 60% efficacy against human immunodeficiency virus (HIV) acquisition at 1 year

24 Following our findings on the anti-human immunodeficiency virus (HIV) activity of acyclovir

25 le of sexual networks in the epidemiology of human immunodeficiency virus (HIV) among black men who h

26 ealthcare quality and access for people with human immunodeficiency virus (HIV) and acquired immune d

27 ide ART availability, the burden of advanced human immunodeficiency virus (HIV) and associated opport

28 virologic control in children infected with human immunodeficiency virus (HIV) and exposed to nevira

29 longitudinal cohort of women coinfected with human immunodeficiency virus (HIV) and hepatitis C virus

30 Co-regulation of human immunodeficiency virus (HIV) and human C-X-C chemo

31 Human immunodeficiency virus (HIV) and simian immunodefi

32 ed threonine near the C terminus of gp120 of human immunodeficiency virus (HIV) and simian immunodefi

33 ween an exposure resulting in infection with human immunodeficiency virus (HIV) and when a test can r

34 Patients with human immunodeficiency virus (HIV) and/or chronic hepati

35 Human immunodeficiency virus (HIV) antibodies are genera

36 co-infected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of l

37 d to ensuring that 90% of people living with human immunodeficiency virus (HIV) are diagnosed, 90% st

38 Youths aged 13 to 24 years old living with human immunodeficiency virus (HIV) are less likely than

39 umbers of children infected perinatally with human immunodeficiency virus (HIV) are surviving to adol

40 n 6 US cities, had negative test results for human immunodeficiency virus (HIV) but were at high risk

41 ressed) viral suppression among persons with human immunodeficiency virus (HIV) by 2020.

42 Perinatal transmission of human immunodeficiency virus (HIV) can be reduced throug

43 The ongoing tuberculosis-human immunodeficiency virus (HIV) coepidemic and rising

44 ve been similar in patients with and without human immunodeficiency virus (HIV) coinfection; however,

45 the successful design and implementation of human immunodeficiency virus (HIV) curative strategies i

46 es: no IR testing vs IR testing performed at human immunodeficiency virus (HIV) diagnosis.

47 Pain has always been an important part of human immunodeficiency virus (HIV) disease and its exper

48 egnancy is important for control of maternal human immunodeficiency virus (HIV) disease and the preve

49 Facial lipoatrophy (FLA) is associated with human immunodeficiency virus (HIV) disease and the use o

50 , strongly predicts mortality during treated human immunodeficiency virus (HIV) disease in Ugandans a

51 cult to assess the role of thymic failure in human immunodeficiency virus (HIV) disease progression.

52 During human immunodeficiency virus (HIV) disease, chronic immu

53 se, which represents a target for novel anti-human immunodeficiency virus (HIV) drug development.IMPO

54 e a driving factor behind the development of human immunodeficiency virus (HIV) drug resistance (HIVD

55 The emergence and spread of human immunodeficiency virus (HIV) drug resistance from

56 In Western countries emergence of human immunodeficiency virus (HIV) drug resistance has t

57 High-quality, simplified, and low-cost human immunodeficiency virus (HIV) drug resistance tests

58 s are associated with clinically significant human immunodeficiency virus (HIV) drug resistance, assa

59 mic distribution of cell subsets that harbor human immunodeficiency virus (HIV) during antiretroviral

60 iven the well-documented viral archeology of human immunodeficiency virus (HIV) emergence following h

61 enders and populations at risk toward global human immunodeficiency virus (HIV) epidemic control.

62 The human immunodeficiency virus (HIV) epidemic in Ukraine h

63 A long-standing question of human immunodeficiency virus (HIV) genetic variation and

64 Human immunodeficiency virus (HIV) has a number of circu

65 Human immunodeficiency virus (HIV) has been associated w

66 neutralizing antibodies directed against the human immunodeficiency virus (HIV) has received consider

67 n of mother-to-child transmission (PMTCT) of human immunodeficiency virus (HIV) have been scaled up i

68 as implemented in response to an outbreak of human immunodeficiency virus (HIV) infection among perso

69 Black women bear the highest burden of human immunodeficiency virus (HIV) infection among US wo

70 Bone loss occurs in human immunodeficiency virus (HIV) infection but paradox

71 eveloped countries has changed the course of Human Immunodeficiency Virus (HIV) infection from an alm

72 ociation of coronary heart disease (CHD) and human immunodeficiency virus (HIV) infection has been we

73 It is recognized that human immunodeficiency virus (HIV) infection increases t

74 Human immunodeficiency virus (HIV) infection is a recogn

75 wer potential to induce hepatic steatosis in human immunodeficiency virus (HIV) infection need to be

76 Cure of Human Immunodeficiency Virus (HIV) infection remains elu

77 m in 102 asymptomatic Air Force members with human immunodeficiency virus (HIV) infection revealed 19

78 t gains in the treatment of tuberculosis and human immunodeficiency virus (HIV) infection worldwide.

79 is (PrEP) is highly effective for preventing human immunodeficiency virus (HIV) infection, but risk c

80 for adverse birth outcomes among women with human immunodeficiency virus (HIV) infection, but whethe

81 In human immunodeficiency virus (HIV) infection, host facto

82 uent cause of meningitis in individuals with human immunodeficiency virus (HIV) infection, resulting

83 Saharan Africa, among patients with advanced human immunodeficiency virus (HIV) infection, the rate o

84 ity compounds the negative health effects of human immunodeficiency virus (HIV) infection.

85 gnosing active tuberculosis in patients with human immunodeficiency virus (HIV) infection.

86 effective strategy to prevent acquisition of human immunodeficiency virus (HIV) infection.

87 me a major complication for individuals with human immunodeficiency virus (HIV) infection.

88 This may be especially true in chronic human immunodeficiency virus (HIV) infection.

89 In January 2015, an outbreak of undiagnosed human immunodeficiency virus (HIV) infections among pers

90 individuals with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections, but the i

91 ell dysfunction observed in simian (SIV) and human immunodeficiency virus (HIV) infections.

92 Epithelium-Derived Growth Factor (LEDGF) and human immunodeficiency virus (HIV) integrase is an impor

93 A thorough understanding of the role of human immunodeficiency virus (HIV) intrahost evolution i

94 g the quality, and proactively using data of human immunodeficiency virus (HIV) load testing are pivo

95 Patients coinfected with syphilis and human immunodeficiency virus (HIV) may have a slower dec

96 of a combination strategy for prevention of human immunodeficiency virus (HIV) on the incidence of H

97 The Human Immunodeficiency Virus (HIV) Organ Policy Equity A

98 As the epidemiological epicenter of the human immunodeficiency virus (HIV) pandemic, the Democra

99 4657412 polymorphism on the adaptive WMT, in human immunodeficiency virus (HIV) participants compared

100 ch other's replication and perhaps affecting human immunodeficiency virus (HIV) pathogenesis and dise

101 nt-of-care (POC) diagnostic technologies for human immunodeficiency virus (HIV) patients in resource-

102 Maraviroc (MVC) is a candidate for human immunodeficiency virus (HIV) pre-exposure prophyla

103 rom 34,446 respondents to a tuberculosis and human immunodeficiency virus (HIV) prevalence survey tha

104 losis (TB) risk in populations infected with human immunodeficiency virus (HIV) remain understudied,

105 Human immunodeficiency virus (HIV) remains a significant

106 TARBP2) is known to play important roles in human immunodeficiency virus (HIV) replication and micro

107 Human immunodeficiency virus (HIV) reverse transcriptase

108 A human immunodeficiency virus (HIV) risk assessment tool

109 s regarding the time course and magnitude of human immunodeficiency virus (HIV) RNA decay in semen.

110 ne activation is suspected to modulate local human immunodeficiency virus (HIV) RNA levels and the ri

111 Genital human immunodeficiency virus (HIV) RNA shedding can cont

112 rment persists despite suppression of plasma human immunodeficiency virus (HIV) RNA.

113 adly neutralizing antibodies (bNAbs) against human immunodeficiency virus (HIV) show great promise in

114 itude), moderate malnutrition, or an unknown human immunodeficiency virus (HIV) status in an HIV-ende

115 cause substantial disease and death despite human immunodeficiency virus (HIV) suppression with anti

116 posure prophylaxis programs involve frequent human immunodeficiency virus (HIV) testing.

117 irus (HR-HPV) is higher in women living with human immunodeficiency virus (HIV) than in the general p

118 Persons with human immunodeficiency virus (HIV) that is treated with

119 Genital inflammation is a key determinant of human immunodeficiency virus (HIV) transmission, and may

120 The long-term effectiveness of human immunodeficiency virus (HIV) treatments containing

121 A laboratory worker was infected with human immunodeficiency virus (HIV) type 1 in a biosafety

122 Human immunodeficiency virus (HIV) type 1 uses the CD4 m

123 An important goal of human immunodeficiency virus (HIV) vaccine design is ide

124 lattice formed by the capsid protein (CA) of human immunodeficiency virus (HIV) was self-assembled as

125 Individuals infected with human immunodeficiency virus (HIV) who have previously h

126 for the majority of individuals living with human immunodeficiency virus (HIV) worldwide.

127 diseases (NCDs) among individuals aging with human immunodeficiency virus (HIV), but few studies have

128 use is prevalent among persons infected with human immunodeficiency virus (HIV), but its long-term ef

129 HCV-positive persons and excluded those with human immunodeficiency virus (HIV), hepatitis B surface

130 n recipients at increased risk for acquiring human immunodeficiency virus (HIV), hepatitis B virus (H

131 lobally 1.8 million children are living with human immunodeficiency virus (HIV), yet only 51% of thos

132 The native kidney is a reservoir for human immunodeficiency virus (HIV)-1 and a site of viral

133 PC) directs the localization and assembly of human immunodeficiency virus (HIV)-1 Gag polyprotein at

134 we report that the tetraspanin CD81 enhances human immunodeficiency virus (HIV)-1 reverse transcripti

135 that predict the preventative efficacy of a human immunodeficiency virus (HIV)-1 vaccine.

136 phages may lead to improved understanding of human immunodeficiency virus (HIV)-associated cardiovasc

137 Human immunodeficiency virus (HIV)-associated heart dise

138 s among hospitalized patients diagnosed with human immunodeficiency virus (HIV)-associated tuberculos

139 ith drug-susceptible tuberculosis (including human immunodeficiency virus (HIV)-coinfected cases) and

140 Human immunodeficiency virus (HIV)-exposed infants are d

141 Older human immunodeficiency virus (HIV)-infected adults may e

142 ) is widely used in malaria-endemic areas in human immunodeficiency virus (HIV)-infected children and

143 The incidence of clinical events in human immunodeficiency virus (HIV)-infected HCV-seroposi

144 tivation and inflammation remain elevated in human immunodeficiency virus (HIV)-infected individuals

145 Our data-driven model tracked human immunodeficiency virus (HIV)-infected individuals

146 Human immunodeficiency virus (HIV)-infected individuals

147 e general population, but their frequency in human immunodeficiency virus (HIV)-infected individuals

148 scontinuation increases malaria incidence in human immunodeficiency virus (HIV)-infected individuals.

149 Depression affects up to 30% of human immunodeficiency virus (HIV)-infected individuals.

150 Disease progression is rapid in human immunodeficiency virus (HIV)-infected infants.

151 tted hepatitis C virus (HCV) infection among human immunodeficiency virus (HIV)-infected men who have

152 sarcoma (KS), one of the leading cancers in human immunodeficiency virus (HIV)-infected patients in

153 The effect of tracing human immunodeficiency virus (HIV)-infected patients who

154 Selected human immunodeficiency virus (HIV)-infected patients wit

155 Quantify proportion of human immunodeficiency virus (HIV)-infected patients wit

156 based on transient elastography (TE), among human immunodeficiency virus (HIV)-infected patients wit

157 ommunity-recruited prospective cohort of 961 human immunodeficiency virus (HIV)-infected people who i

158 uidelines recommend that all sexually active human immunodeficiency virus (HIV)-infected persons be t

159 n interventions for prevention of malaria in human immunodeficiency virus (HIV)-infected pregnant wom

160 We characterized patterns of TDR among human immunodeficiency virus (HIV)-infected PWUD, and as

161 with the increased morbimortality of chronic human immunodeficiency virus (HIV)-infected subjects.

162 Human immunodeficiency virus (HIV)-infected women have a

163 The numbers of human immunodeficiency virus (HIV)-infected women initia

164 Over one menstrual cycle, 20 human immunodeficiency virus (HIV)-infected women virolo

165 Longitudinal data were analyzed from human immunodeficiency virus (HIV)-infected women who be

166 Most human immunodeficiency virus (HIV)-infected youths are u

167 n human papillomavirus (HPV) infection among human immunodeficiency virus (HIV)-negative or HIV-posit

168 Among 601 human immunodeficiency virus (HIV)-negative tested contr

169 sociation with increased suicidal risk among human immunodeficiency virus (HIV)-positive adults in Ug

170 We included cohort data of human immunodeficiency virus (HIV)-positive adults who s

171 Neurocognitive disorders remain common among human immunodeficiency virus (HIV)-positive adults, perh

172 are and antiretroviral (ARV) treatment among human immunodeficiency virus (HIV)-positive men who have

173 d effective diagnostic algorithms for use in human immunodeficiency virus (HIV)-positive patients are

174 We compared estimated costs of retesting human immunodeficiency virus (HIV)-positive persons befo

175 With an increasing number of human immunodeficiency virus (HIV)-positive persons seek

176 yces marneffei infection is a major cause of human immunodeficiency virus (HIV)-related death in Sout

177 linical trials evaluating IIV efficacy among human immunodeficiency virus (HIV)-uninfected and HIV-in

178 ti-Ethnic Study of Atherosclerosis (MESA), a Human Immunodeficiency Virus (HIV)-uninfected cohort, wh

179 LTA4H genotype predicted survival of human immunodeficiency virus (HIV)-uninfected patients,

180 e demonstrated improved birth outcomes among human immunodeficiency virus (HIV)-uninfected pregnant w

181 bine (FTC) preexposure prophylaxis (PrEP) in human immunodeficiency virus (HIV)-uninfected young men

182 cularly in individuals who are infected with human immunodeficiency virus (HIV).

183 HIV/AIDS (UNAIDS) issued treatment goals for human immunodeficiency virus (HIV).

184 th known status, 38 (59%) were infected with human immunodeficiency virus (HIV).

185 rwise effectively treated people living with human immunodeficiency virus (HIV).

186 y has enabled people to live long lives with human immunodeficiency virus (HIV).

187 development of a protective vaccine against human immunodeficiency virus (HIV).

188 lications for the design of vaccines against human immunodeficiency virus (HIV).

189 otect human beings against various clades of Human Immunodeficiency Virus (HIV).

190 ed gut causes increased immune activation in human immunodeficiency virus (HIV).

191 eveloping a vaccine and novel treatments for human immunodeficiency virus (HIV).

192 testing for the causative agent of AIDS, the human immunodeficiency virus (HIV).

193 owledge gaps remain about how the Ryan White human immunodeficiency virus (HIV)/AIDS Program (RW) con

194 n in a large cohort of women coinfected with human immunodeficiency virus (HIV)/HCV.

195 Large cohorts are needed to assess human immunodeficiency virus (HIV)/hepatitis C virus (HC

196 NLR-NAR) events and mortality in a cohort of human immunodeficiency virus (HIV)/hepatitis C virus (HC

197 are accessory proteins encoded by different human immunodeficiency virus (HIV)/simian immunodeficien

198 Extensive immunopathology occurs in human immunodeficiency virus (HIV)/tuberculosis (TB) coi

199 ntravaginal practices may be associated with human immunodeficiency virus (HIV-1) infection risk; how

200 es have been reported in persons living with human immunodeficiency virus (HIV; PLWH) who are receivi

201 cause of morbidity among persons living with human immunodeficiency virus (HIV; PLWH).

202 patitis C virus (HCV)-infected subjects (31% human immunodeficiency virus [HIV] positive) pre- and po

203 aged 49 [12.5] years, 31 [47%] of whom were human immunodeficiency virus [HIV]+) were analyzed.

204 nfluenza virus, respiratory syncytial virus, human immunodeficiency virus, human T cell leukemia viru

205 A total of 817 human immunodeficiency virus-infected Ethiopians with CD

206 Human immunodeficiency virus-infected individuals on cAR

207 ervational cohort study was conducted in 302 human immunodeficiency virus-infected patients who had a

208 AM lateral flow assay (LF-LAM) results among human immunodeficiency virus-infected patients with diss

209 isk is greatly increased in immunosuppressed human immunodeficiency virus-infected people.

210 Pregnancy outcomes of perinatally human immunodeficiency virus-infected women (PHIV) are p

211 As perinatally human immunodeficiency virus-infected youth (PHIVY) in t

212 om 13 European and North American cohorts of human immunodeficiency virus-infected, antiretroviral th

213 sporidiosis (CD40 ligand deficiency [n = 1], human immunodeficiency virus infection [n = 4]).

214 Human immunodeficiency virus infection induces a wide ra

215 act lens wearers (P = 0.21) or patients with human immunodeficiency virus infection or AIDS (P = 0.60

216 Human immunodeficiency virus infection was independently

217 Human immunodeficiency virus infection, traditional CKD

218 Human immunodeficiency virus infection.

219 betes and obesity) and major infections like human immunodeficiency virus infection.

220 We prospectively evaluated human immunodeficiency virus-negative adults (n = 64) wi

221 at cancer diagnosis among people living with human immunodeficiency virus (PLWH).

222 se of morbidity and mortality in people with human immunodeficiency virus (PWHIV) on effective antire

223 s in this area; (3) lessons learned from the human immunodeficiency virus research field, where pregn

224 nation of M41L + L210W + T215rev showed full human immunodeficiency virus RNA suppression while recei

225 d, previously reported to be an inhibitor of human immunodeficiency virus RNase H, inhibited pUL89 en

226 alent-vaccine-immunized macaques from simian-human immunodeficiency virus (SHIV) challenge.

227 potently inhibited in vivo HIV-1 and simian-human immunodeficiency virus (SHIV) infection in humaniz

228 administration of bNAbs in a macaque simian/human immunodeficiency virus (SHIV) model is associated

229 y incompletely neutralize the clade C simian-human immunodeficiency virus (SHIV) stock (SHIV-327c) at

230 solates in vitro and protects against simian-human immunodeficiency virus (SHIV) when delivered paren

231 tion data from macaques infected with simian/human immunodeficiency virus (SHIV), we observe a lower

232 lycan antibody PGT121, in chronically simian-human immunodeficiency virus (SHIV)-SF162P3-infected mac

233 ere, we infected rhesus macaques with simian-human immunodeficiency viruses (SHIV) and followed the d

234 for demographics, clinical characteristics, human immunodeficiency virus status, and period of treat

235 profile, low body mass index (<18.5 kg/m2), human immunodeficiency virus status, and study site, par

236 nt for sociodemographics, substance use, and human immunodeficiency virus status.

237 itis, and reactive arthritis and facilitates human immunodeficiency virus transmission in men is weak

238 reproductive health in women and/or prevent human immunodeficiency virus transmission.

239 marker, and early mortality in patients with human immunodeficiency virus/tuberculosis co-infection.

240 lex virus type 2 (HSV-2; herpes) exacerbates human immunodeficiency virus type 1 (HIV) by unclear mec

241 Progressive T cell depletion during chronic human immunodeficiency virus type 1 (HIV) infection is a

242 Immune control of human immunodeficiency virus type 1 (HIV) infection is t

243 Human immunodeficiency virus type 1 (HIV) infection subs

244 been shown to be preferentially targeted by human immunodeficiency virus type 1 (HIV-1) and are impl

245 ned elusive for important pathogens, such as human immunodeficiency virus type 1 (HIV-1) and herpesvi

246 reporter genes delivered by vectors based on human immunodeficiency virus type 1 (HIV-1) and Mason-Pf

247 Human immunodeficiency virus type 1 (HIV-1) assembles as

248 Although the human immunodeficiency virus type 1 (HIV-1) CA carboxy-t

249 Human immunodeficiency virus type 1 (HIV-1) can replicat

250 The human immunodeficiency virus type 1 (HIV-1) capsid prote

251 of measles and associations with outcome and human immunodeficiency virus type 1 (HIV-1) coinfection,

252 Monitoring human immunodeficiency virus type 1 (HIV-1) drug resista

253 Human immunodeficiency virus type 1 (HIV-1) drug resista

254 Human immunodeficiency virus type 1 (HIV-1) entry into c

255 ing conserved CD4-induced (CD4i) epitopes on human immunodeficiency virus type 1 (HIV-1) Env and able

256 s between the gp120 and gp41 subunits of the human immunodeficiency virus type 1 (HIV-1) envelope gly

257 s maintained in a quiescent state.IMPORTANCE Human immunodeficiency virus type 1 (HIV-1) establishes

258 es maintain the ability to interact with the human immunodeficiency virus type 1 (HIV-1) Gag precurso

259 velope glycoprotein (Env) trimers of various human immunodeficiency virus type 1 (HIV-1) genotypes ar

260 virtide) and other peptides derived from the human immunodeficiency virus type 1 (HIV-1) gp41 C-termi

261 The hydrophobic groove of the human immunodeficiency virus type 1 (HIV-1) gp41 NHR tri

262 al components of vaccine-induced immunity to human immunodeficiency virus type 1 (HIV-1) in humans an

263 In the absence of therapy, CXCR4 (X4)-tropic human immunodeficiency virus type 1 (HIV-1) increases ov

264 usceptible tuberculosis in a setting of high human immunodeficiency virus type 1 (HIV-1) infection an

265 iescent proviral genomes that persist during human immunodeficiency virus type 1 (HIV-1) infection de

266 Human immunodeficiency virus type 1 (HIV-1) infection is

267 Human immunodeficiency virus type 1 (HIV-1) infection is

268 Human immunodeficiency virus type 1 (HIV-1) infection of

269 e HCV infection in participants with chronic human immunodeficiency virus type 1 (HIV-1) infection.

270 ete roles and functions of DRFs during early human immunodeficiency virus type 1 (HIV-1) infection.

271 of CD4+ T lymphocytes, a major reservoir for human immunodeficiency virus type 1 (HIV-1) infection.

272 High numbers of human immunodeficiency virus type 1 (HIV-1) infections a

273 Rhesus macaques are used to model human immunodeficiency virus type 1 (HIV-1) infections,

274 A hallmark of retroviruses such as human immunodeficiency virus type 1 (HIV-1) is reverse t

275 Human immunodeficiency virus type 1 (HIV-1) is the resul

276 GSK3532795 is a second-generation human immunodeficiency virus type 1 (HIV-1) maturation i

277 The envelope glycoproteins (Envs) from human immunodeficiency virus type 1 (HIV-1) mediate vira

278 Minority variant human immunodeficiency virus type 1 (HIV-1) nonnucleosid

279 Human immunodeficiency virus type 1 (HIV-1) persists in

280 Local Alignment Program (LAP) using 115,118 human immunodeficiency virus type 1 (HIV-1) protease, re

281 Little is known about the fraction of human immunodeficiency virus type 1 (HIV-1) proviruses t

282 (HCV) infection in patients coinfected with human immunodeficiency virus type 1 (HIV-1) remains a me

283 (ART) limits proviral reservoirs, a goal for human immunodeficiency virus type 1 (HIV-1) remission st

284 Full-length human immunodeficiency virus type 1 (HIV-1) RNA serves a

285 Full-length unspliced human immunodeficiency virus type 1 (HIV-1) RNAs serve d

286 vir plus 2 nucleos(t)ides for maintenance of human immunodeficiency virus type 1 (HIV-1) suppression.

287 ith latency reversing agents (LRAs) enhances human immunodeficiency virus type 1 (HIV-1) transcriptio

288 design are being developed as immunogens in human immunodeficiency virus type 1 (HIV-1) vaccine deve

289 important role in regulating the assembly of human immunodeficiency virus type 1 (HIV-1) virus partic

290 Many viruses, including human immunodeficiency virus type 1 (HIV-1), encode a re

291 e strong dependence of retroviruses, such as human immunodeficiency virus type 1 (HIV-1), on host cel

292 ess to AIDS, in stark contrast to pathogenic human immunodeficiency virus type 1 (HIV-1)-human and SI

293 lated with rotavirus vaccine responses in 68 human immunodeficiency virus type 1 (HIV-1)-infected (an

294 a, has long been known to be elevated in the human immunodeficiency virus type 1 (HIV-1)-infected bra

295 are reported in uninfected children born to human immunodeficiency virus type 1 (HIV-1)-infected wom

296 tion with an anti-PD-L1 antibody may improve human immunodeficiency virus type 1 (HIV-1)-specific imm

297 IVgor, which represent the ape precursors of human immunodeficiency virus type 1 (HIV-1).

298 The human immunodeficiency virus type 1 (HIV-1)/simian immun

299 ized Rous sarcoma virus (RSV) intasomes with human immunodeficiency virus type 1 strand transfer inhi

300 Human immunodeficiency virus type-1 (HIV-1)-associated n